• Explore /
  • Poster
  • / SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).

SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).

Abstract Poster

Authors

null

Santiago Escrivá

Medical Oncology Department, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Santiago Escrivá , Seock-Ah Im , Fatima Cardoso , Javier Cortes , Giuseppe Curigliano , William John Gradishar , Mark D. Pegram , Gail Lynn Shaw Wright , Christelle Levy , Michelino De Laurentiis , Jean-Marc Ferrero , Shakeela Wazeen Bahadur , Sung-Bae Kim , Katarína Petráková , David A. Riseberg , Denise A. Yardley , Sutton Edlich , Sam Hong , Edwin P. Rock , Hope S. Rugo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT02492711

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1040)

DOI

10.1200/JCO.2020.38.15_suppl.1040

Abstract #

1040

Poster Bd #

125

Abstract Disclosures

Similar Posters

First Author: Hope S. Rugo

First Author: Zhonghui Ou

First Author: Kathy Miller

First Author: Yutaka Yamamoto